News archive
Showing 745 results
October 2025
-
Media Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across… -
Media Release
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell… -
Story Hope
Underserved but Not Out of Reach: 3 Ways to Bridge Care Gaps in Communities to Improve Advanced Prostate Cancer
Creating truly equal care for patients with advanced prostate cancer begins by learning from those often overlooked and help them feel seen, heard, and understood.
-
Media Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo… -
Story Education and Awareness
Five Questions with Katie Mazuk, Novartis US Chief Patient Experience Officer
In this interview, Katie shares the experiences that have shaped her leadership philosophy, her vision for pioneering new approaches in patient support, and why she believes the future of healthcare lies in combining technological innovation with genuine connection.
-
Media Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-… -
Media Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor… -
Media Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1… -
Story Education and Awareness
High Lipoprotein(a) Explained: What You Need to Know about This Hidden, Emerging Indicator for Heart Disease
High Lp(a) is an inherited condition that can independently increase the risk of heart disease1,2,3. Read on.
-
Story Education and Awareness
5 Key Insights Into How Women Really Feel About Their Breasts
How do women’s feelings about their breasts impact breast health? We asked 3000 women in the first ever Novartis Breast Health & Experience Index.